Dimension Capital
VC Fund
New York, United States
Dimension Capital is a VC fund in New York focused on Biotechnology and Software. Dimension is a first-of-its-kind firm partnering with founders at the interface of technology and life sciences to transform the trajectory of life on earth. The firm partners with leading entrepreneurs to build the next generation of tech and bio businesses. The company was founded by Nan Li, Adam Goulburn, and Zavain Dar in March 2022 and isbased in New York, NY and San Francisco, CA.
- Total investments:
- 26
- Last investment:
- Lead investor:
- 50%
- Fund size:
- $350M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Dimension Capital invests in
Stages Dimension Capital invests in
Countries Dimension Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adam Goulburn
|
|||
Michele Vlcek
|
|||
Nan Li
|
|||
2 more contacts available
Investment Focus
Industry
- Biotechnology 11 (42%)
- Software 5 (19%)
- Health Care 4 (15%)
- Artificial Intelligence 4 (15%)
- Medical 2 (8%)
Stage
- Seed 7 (27%)
- Series A 5 (19%)
- Series B 4 (15%)
- Venture - Series Unknown 3 (12%)
- Series D 2 (8%)
Country
- United States 13 (50%)
- Canada 2 (8%)
- Japan 1 (4%)
- Germany 1 (4%)
- United Kingdom 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Adam Goulburn
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 17 | Find email | |
|
Michele Vlcek
Operations Manager
|
Operations Manager | Total investments: 0 | Find email | |
|
Nan Li
Co-Founder
|
Co-Founder | Total investments: 16 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Earendil Labs
|
Earendil Labs is a biotechnology company developing technology platforms that transform therapeutic protein discovery. | $787M / Venture - Series Unknown / Mar 20, 2026 | |
Congruence Therapeutics
|
Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. | $39.5M / Venture - Series Unknown / Mar 19, 2026 | |
Tamarind Bio
|
Tamarind Bio is a software company that help the scientists and researchers using computational tools in biology. | $13.6M / Series A / Feb 24, 2026 | |
Automata
|
Automata is a deep-tech company that creates products that empower people to automate physical work. The company's product, Eva, is a lightweight and affordable robot arm built for professionals in a production line, in a lab, a home workshop or even in a classroom. People don't need to be technical experts to communicate with robots. Theweb-based software platform can be programmed by anyone, anywhere, any time, from any device, making it easy to reconfigure for a wide range of different tasks.Automata was founded on 2015 and is headquartered in London, England. | $45M / Series C / Jan 29, 2026 | |
Chai Discovery
|
Chai Discovery creates Chai-1, a multi-modal foundation model designed for predicting molecular structures relevant to drug discovery. The model facilitates the unified prediction of proteins, small molecules, and nucleic acids, and is available for free for commercial applications. By enabling accurate predictions without the need for multiplesequence alignments, Chai-1 advances the capabilities of molecular modeling in the life sciences. | $130M / Series B / Dec 15, 2025 | |
NewLimit
|
NewLimit specializes in treating age-related diseases to extend the human health span. It works on developing epigenetic reprogramming medicines to treat diseases with large unmet needs. | $45M / Convertible Note / Oct 20, 2025 | |
Odyssey Therapeutics
|
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $213M / Series D / Sep 10, 2025 | |
Enveda Biosciences
|
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $150M / Series D / Sep 04, 2025 | |
Fiveonefour
|
We build the frameworks, tools, and infrastructure that developers need to quickly prototype, productize, and operationalize analytical workflows. | $17M / Series A / Sep 04, 2025 | |
Convoke
|
Convoke is curating high-quality datasets, automating workflows, and building a software platform. | $8.6M / Seed / Aug 19, 2025 | |
| See all 26 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Dimension Capital invest in?
Dimension Capital invests primarily in Biotechnology, Software and Health Care startups, most often at Seed and Series A stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Dimension Capital?
Public channels for Dimension Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Dimension Capital?
The team at Dimension Capital includes Adam Goulburn (Founder & Managing Partner), Michele Vlcek (Operations Manager) and Nan Li (Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
